You are here: Industry Insights > AstraZeneca

News List

AstraZeneca to Divest US Synagis Rights to Sobi americanpharmaceuticalreview
November 14, 2018
AstraZeneca to Divest US Synagis Rights to Sobi
AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn pharmatimes
November 14, 2018
AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory syncytial virus (RSV)...
AstraZeneca divests US rights to Synagis pharmatimes
November 14, 2018
Swedish Orphan Biovitrum AB has entered into an agreement to buy US rights to AstraZeneca’s Synagis, licensed for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV).
AstraZeneca sells US rights to RSV therapy Synagis to Sobi for $1.5 billion upfront firstwordpharma
November 13, 2018
AstraZeneca announced Tuesday an agreement to sell US rights to Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for a total upfront consideration of $1.5 billion, including $1 billion in cash. Under the deal for the respiratory syncytial virus (R
AstraZeneca, Merck's Lynparza scores speedy review in blockbuster ovarian cancer market fiercepharma
November 13, 2018
Last month, AstraZeneca and Merck’s Lynparza posted big-time ovarian cancer data, and regulators are taking note.
NICE provisionally knocks back AstraZeneca's PARP inhibitor Lynparza in ovarian cancer maintenance setting pharmafile
November 12, 2018
The National Institute for Health and Care Excellence (NICE) issued draft guidance Friday recommending against routine NHS funding of AstraZeneca's Lynparza (olaparib) for
AstraZeneca's Farxiga staves off cardiac death, hospitalisation for heart failure in broad patient population with type 2 diabetes pharmafile
November 12, 2018
AstraZeneca presented detailed results from the DECLARE-TIMI 58 study at the American Heart Association (AHA) conference showing that Farxiga (dapagliflozin) met the co-primary
AstraZeneca gets back to growth, but can it hit $40B by 2023? CEO says yes—again biospectrum
November 12, 2018
AstraZeneca CEO Pascal Soriot has repeatedly said his company would finally get back on the upswing in the second half of this year, and he’s put skeptics to rest with strong third-quarter numbers.
AstraZeneca gets back to growth, but can it hit $40B by 2023? CEO says yes—again fiercepharma
November 11, 2018
AstraZeneca CEO Pascal Soriot has repeatedly said his company would finally get back on the upswing in the second half of this year, and he’s put skeptics to rest with strong third-quarter numbers. Now, he’s doubling down on an even more ambitious promise
AstraZeneca to sell drug rights to Covis Pharma in $371m deal pharmaceutical-technology
November 10, 2018
AstraZeneca has agreed to divest its rights for Alvesco (ciclesonide), Omnaris and Zetonna (ciclesonide) medicines to Swiss speciality pharmaceutical firm Covis Pharma in a deal valued up to $371m.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page